TrianglePUBLICATIONS · 34655533
Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial.
Open original source → · Download preserved record
Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.
- Journal
- Lancet Oncol
- Publication date
- 2021 Nov
- First author
- Facon T
Publication notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
Authors and identifiers
- name
- Facon T
- type
- Author
- name
- Kumar SK
- type
- Author
- name
- Plesner T
- type
- Author
- name
- Orlowski RZ
- type
- Author
- name
- Moreau P
- type
- Author
- name
- Bahlis N
- type
- Author
- name
- Basu S
- type
- Author
- name
- Nahi H
- type
- Author
- name
- Hulin C
- type
- Author
- name
- Quach H
- type
- Author
- name
- Goldschmidt H
- type
- Author
- name
- O'Dwyer M
- type
- Author
Complete bibliographic record and source provenance
- authors
- name
- Facon T
- type
- Author
- name
- Kumar SK
- type
- Author
- name
- Plesner T
- type
- Author
- name
- Orlowski RZ
- type
- Author
- name
- Moreau P
- type
- Author
- name
- Bahlis N
- type
- Author
- name
- Basu S
- type
- Author
- name
- Nahi H
- type
- Author
- name
- Hulin C
- type
- Author
- name
- Quach H
- type
- Author
- name
- Goldschmidt H
- type
- Author
- name
- O'Dwyer M
- type
- Author
- bibliography ids
- nci-bib-01a53fc594adb24593273a55
- book metadata
- content sha256
- 70d78c78e2dd358e3701a5f7f9c97719ce3429d3d7172b79ae10a3f60e68cad0
- document type
- citation
- dois
- 10.1016/S1470-2045(21)00466-6
- electronic publication date
- display
- 2021 Oct 13
- precision
- day
- year
- 2021
- evidence scope
- bibliographic_metadata_only
- id
- pubmed:34655533
- immutable id
- pubmed:34655533@70d78c78e2dd358e3701a5f7f9c97719ce3429d3d7172b79ae10a3f60e68cad0
- journal
- abbreviation
- Lancet Oncol
- issn electronic
- 1474-5488
- issn print
- 1470-2045
- issue
- 11
- name
- The Lancet. Oncology
- nlm unique id
- 100957246
- pages
- 1582-1596
- volume
- 22
- languages
- eng
- notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
- outcomes validated
- false
- pmid
- 34655533
- provenance
- batch id
- 192b6392c165c6b06274
- provider
- NCBI PubMed ESummary
- record sha256
- a805fdf0047ae59b6eb51fd2c2ac15b84f0af6d64bfca07a3b7d2b7e332a42af
- response sha256
- 7d81e9fb11ee99e6ad4116aecd61ba71cd6bf76f2a8f8f6d15c5c85e9c6c56b4
- retrieved at
- 2026-09-09T23:48:02.713075+00:00
- publication date
- display
- 2021 Nov
- precision
- month
- year
- 2021
- publication types
- Clinical Trial, Phase III
- Journal Article
- Multicenter Study
- Randomized Controlled Trial
- Research Support, Non-U.S. Gov't
- record status
- PubMed - indexed for MEDLINE
- schema version
- 1.0
- title
- Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial.
Preserved source evidence · Not medical advice